Andere Sprachen Veru Inc.

Aktien

A2DV3C

US92536C1036

VERU

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:19:12 10.05.2024			% 5 Tage	% 1. Jan.
1,355 ^USD	-1,09 %		-16,87 %	+88,19 %

08.05.	Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024
06.05.	VERU INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	08.05.
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program	08.05.
Veru to Present at the GLP-1 Based Therapeutics Summit	02.05.
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024	01.05.
Veru : Corporate Presentation, May 2024	30.04.
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30.04.
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30.04.
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11	25.04.
Veru Announces Date of 2024 Annual Meeting of Shareholders	01.04.
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	01.04.
Veru Reschedules Annual Meeting of Shareholders	25.03.
Veru Reschedules Annual Meeting of Shareholders	22.03.
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13.03.
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13.03.
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss	12.03.
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	12.03.
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q	28.02.
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN	21.02.
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss	20.02.
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	20.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Veru Inc.

Aktien

A2DV3C

US92536C1036

VERU

Andere Sprachen

Filter